Hebrew University Medical School, Jerusalem, Israel.
Diabetes Metab Res Rev. 2024 Jan;40(1):e3712. doi: 10.1002/dmrr.3712. Epub 2023 Aug 24.
The mammalian target of rapamycin complex 1 syndrome (Tors), paradigm implies an exhaustive cohesive disease entity driven by a hyperactive mTORC1, and which includes obesity, type 2 diabetic hyperglycemia, diabetic dyslipidemia, diabetic cardiomyopathy, diabetic nephropathy, diabetic peripheral neuropathy, hypertension, atherosclerotic cardiovascular disease, non-alcoholic fatty liver disease, some cancers, neurodegeneration, polycystic ovary syndrome, psoriasis and other. The TorS paradigm may account for the efficacy of standard-of-care treatments of type 2 diabetes (T2D) in alleviating the glycaemic and non-glycaemic diseases of TorS in T2D and non-T2D patients. The TorS paradigm may generate novel treatments for TorS diseases.
哺乳动物雷帕霉素靶蛋白复合物 1 综合征（Tors）的发病模式提示一种由 mTORC1 过度激活驱动的包罗万象的疾病实体，它包括肥胖、2 型糖尿病高血糖、糖尿病血脂异常、糖尿病心肌病、糖尿病肾病、糖尿病周围神经病变、高血压、动脉粥样硬化性心血管疾病、非酒精性脂肪性肝病、某些癌症、神经退行性变、多囊卵巢综合征、银屑病等。Tors 发病模式可能解释了标准治疗 2 型糖尿病（T2D）在减轻 T2D 和非 T2D 患者 Tors 患者的血糖和非血糖疾病方面的疗效。Tors 发病模式可能为 Tors 疾病提供新的治疗方法。
